Brief: Mabion Signs LoI With WPD Pharmaceuticals On Extension Of Cooperation
01/10/2026 06:31
BRIEF-Mabion Signs LoI With WPD Pharmaceuticals On Extension Of Cooperation Oct 1 (Reuters) - Mabion SA MABP.WA:
SIGNS LETTER OF INTENT WITH WPD PHARMACEUTICALS REGARDING TALKS ON FUTURE COOPERATION ON DEVELOPMENT OF BIOLOGICAL MEDICINAL PRODUCTS USED IN ONCOLOGY, COVERING PROJECTS RELATED TO ANTIBODY-DRUG CONJUGATES (ADCS)
LETTER OF INTENT REPRESENTS A CONTINUATION OF THE COMPANY'S EXISTING COOPERATION WITH WPD PHARMACEUTICALS AND ITS EXTENSION
LETTER OF INTENT IS NON-BINDING AND REMAINS IN FORCE UNTIL DECEMBER 31, 2026
Source text for Workspace: nEM4HMy1ga
Further company coverage: MABP.WA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Mabion SA
See all newsBrief: Mabion Partner Oddifact Says FDA Consultations Allow MabionCD20 To Be Used As First-Line Therapy For ITP
Brief: Mabion Holds Pre-IND Type B Meeting With FDA On MabionCD20 Development For ITP
Brief: Mabion Signs LoI With WPD Pharmaceuticals On Extension Of Cooperation
Brief: Mabion Q2 Net Loss At 15 Mln Zlotys
Brief: Mabion Signs Deal With Novavax Expanding Cooperation To Analytical Services For Early-Stage Pipeline Projects